Consistency of Drug–Drug and Gene–Drug Interaction Information in US FDA-Approved Drug Labels

Daniela J Conrado1 Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, US FDA, 10903 New Hampshire Avenue, White Oak Building 51, Room 3112, Silver Spring, MD20993, USA;2 Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL32610, USAView further author information

Hobart L Rogers1 Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, US FDA, 10903 New Hampshire Avenue, White Oak Building 51, Room 3112, Silver Spring, MD20993, USAView further author information

Issam Zineh1 Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, US FDA, 10903 New Hampshire Avenue, White Oak Building 51, Room 3112, Silver Spring, MD20993, USAView further author information

Michael A Pacanowski1 Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation & Research, US FDA, 10903 New Hampshire Avenue, White Oak Building 51, Room 3112, Silver Spring, MD20993, USAView further author information

Consistency of Drug–Drug and Gene–Drug Interaction Information in US FDA-Approved Drug Labels

Supplemental Material 1

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Consistency of Drug–Drug and Gene–Drug Interaction Information in US FDA-Approved Drug Labels

Supplemental Material 1

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date